Neuroendocrine differentiation in metastatic prostatic adenocarcinoma Journal Article

  


Authors: Aprikian, A. G.; Cordon-Cardo, C.; Fair, W. R.; Zhang, Z. F.; Bazinet, M.; Hamdy, S. M.; Reuter, V. E.
Article Title: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma
Abstract: Neuroendocrine differentiation of prostatic adenocarcinoma has received considerable attention in recent years. The objectives of this study were to characterize the incidence, pattern of distribution and peptide hormone immunoreactivities of neuroendocrine differentiated tumor cells in prostatic carcinoma metastases; determine the correlation of neuroendocrine differentiation and deoxyribonucleic acid content in lymph node metastases, and determine the prognostic role of neuroendocrine differentiation of metastases in stage D1 cancer. We examined immunohistochemically 62 metastatic lesions (41 pelvic lymph nodes and 21 bone metastases) for the presence of chromogranin-A expressing tumor cells. Of 41 lymph nodes and 21 bone metastases 19 (46%) and 11 (52%), respectively, contained chromogranin- A immunoreactive cells. These cells were commonly found to comprise the minority of tumor cells in the metastases and typically were distributed in a dispersed pattern. Serotonin and peptide hormone immunocytochemistry in 19 cases (12 lymph nodes and 7 bone metastases) demonstrated neuroendocrine cells containing thyroid-stimulating hormone and serotonin in 17 (89%) and 10 (53%), respectively. All 7 bone metastases contained thyroid-stimulating hormone immunoreactive cells. The presence of chromogranin-A positive cells did not correlate statistically with deoxyribonucleic acid content of lymph node metastases nor with disease specific survival in patients with stage D1 prostate cancer. Our results indicate that a substantial proportion of prostate cancer metastases contain a subpopulation of cells expressing a neuroendocrine phenotype similar to primary tumors. These cells are capable of elaborating certain biogenic amines and peptide hormones. However, in stage D1 prostate cancer nodal lesions expressing neuroendocrine differentiation do not appear to have significant prognostic value.
Keywords: adult; human tissue; aged; major clinical study; cancer localization; bone metastasis; lymph node metastasis; cancer incidence; adenocarcinoma; cell differentiation; neuroendocrine tumor; prostatic neoplasms; immunocytochemistry; neoplasm metastasis; cellular distribution; prostate adenocarcinoma; serotonin; chromogranin a; neurosecretory systems; human; male; priority journal; article
Journal Title: Journal of Urology
Volume: 151
Issue: 4
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 1994-04-01
Start Page: 914
End Page: 919
Language: English
DOI: 10.1016/s0022-5347(17)35121-2
PROVIDER: scopus
PUBMED: 8126824
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028214994&doi=10.1016%2fS0022-5347%2817%2935121-2&partnerID=40&md5=9c95ac0af40ca06014731fd9459ddb95
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Carlos Cordon-Cardo
    612 Cordon-Cardo
  2. Victor Reuter
    1228 Reuter
  3. William R Fair
    342 Fair
  4. Zuo-Feng Zhang
    102 Zhang
  5. Armen Aprikian
    18 Aprikian
Related MSK Work